Erasca, Inc. ERAS 深 沪
等待开盘 02-07 09:30:00 美东时间
12.14
+0.260
+2.19%
华盛通- 最 高12.30
- 今 开11.18
- 成交量 82.26万股
- 最 低 3.32
- 昨 收 11.88
- 总市值 148.11万
- 52周最高 12.30
- 市盈率 静 --
- 换手率 674.26%
- 52周最低 0.00
- 委 比 62.12%
- 总股本 0.00亿
- 历史最高 12.30
- 量 比 0.67
- 振 幅 75.59%
- 历史最低 0.00
- 每 手 1
- 风险率 2.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday?
Erasca stock fell Monday despite no company news, after reports said Merck ended acquisition talks with cancer drugmaker Revolution Medicines over valuation differences.
01-26 20:52
Top 2 Industrials Stocks That May Collapse In Q1
As of Jan. 21, 2026, two stocks in the industrials sector could be flashing a r...
01-21 21:56
David Vs. Goliath: Why Small Caps Are Crushing The Magnificent 7
The Russell 2000 is beating the S&P 500 for 10 straight sessions as growth accelerates and small-cap earnings expectations rise.
01-16 05:12
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of AZZ Inc (NYSE:AZZ) rose in pre-market trading after the company repor...
01-08 17:25
Erasca Q3 EPS $(0.11), Inline
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
2025-11-13 05:04
癌王突破，天亮了
（来源：CHC医疗传媒） “癌中之王”胰腺癌的突破，比想象中来得更加快。 9月10日，Revolution Medicines（RVMD）公布Daraxon...
2025-09-16 14:30
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
Erasca announces IND clearance for ERAS-4001 and ERAS-0015 for KRAS-mutant cancers; trials set to begin with initial data expected in 2026.
2025-06-02 12:00
Erasca to Present at Upcoming Investor Conferences in June
Erasca management will participate in two investor conferences in June 2025 and conduct one-on-one meetings. The events include the Jefferies Global Healthcare Conference in New York on June 4 and the Goldman Sachs Global Healthcare Conference in Miami on June 10, both featuring fireside chats.
2025-05-29 12:00
中国渐冻症细胞疗法全球首获FDA正式批准开展注册临床实验｜Healthcare View
士泽生物 全球首款渐冻症再生细胞疗法IND在美获批 士泽生物自主开发的用于治疗渐冻症（即肌萎缩侧索硬化症/ALS/运动神经元症/渐冻人症）的全球首款通用型iP...
2025-02-28 08:02
中国渐冻症细胞疗法全球首获FDA正式批准开展注册临床实验｜Healthcare View
士泽生物 全球首款渐冻症再生细胞疗法IND在美获批 士泽生物自主开发的用于治疗渐冻症（即肌萎缩侧索硬化症/ALS/运动神经元症/渐冻人症）的全球首款通用型iP...
2025-02-28 08:02
